Bildkälla: Stockfoto

Sedana Medical: Updated FDA timeline and Q2 preview - Redeye

Redeye lowers its fair value range following the updated FDA timeline, which will likely hold the share back from any sustainable positive momentum for some time. Moreover, we provide our Q2 2023 preview for the report due on July 21.

Redeye lowers its fair value range following the updated FDA timeline, which will likely hold the share back from any sustainable positive momentum for some time. Moreover, we provide our Q2 2023 preview for the report due on July 21.
Börsvärldens nyhetsbrev
ANNONSER